Wells Fargo Downgrades ShockWave Medical to Equal-Weight, Announces $235 Price Target
Wells Fargo analyst Larry Biegelsen downgrades ShockWave Medical (NASDAQ:SWAV) from Overweight to Equal-Weight and announces $235 price target.
Jim Cramer Says ‘There’s Too Much Political Risk’ For This Stock Is Up 106% In 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is a "very early stage company that has a lot in the pipe. I tend to like these companies."
ShockWave Medical Q3 EPS $0.92 Beats $0.67 Estimate, Sales $131.33M Beat $123.97M Estimate
ShockWave Medical (NASDAQ:SWAV) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.67 by 37.31 percent. This is a 1740 percent increase over earnings of $0.05 per share from
Earnings Scheduled For November 7, 2022
Companies Reporting Before The Bell
• NAPCO Security Techs (NASDAQ:NSSC) is expected to report quarterly earnings at $0.13 per share on revenue of $36.34 million.
Shockwave Confirms Consistent Outcomes For IVL In The Largest Prospective “Real World” Study Of Patients With Heavily Calcified Peripheral Arterial Disease
Shockwave Medical, Inc. (NASDAQ:SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the final 1,373-patient cohort
Morgan Stanley Maintains Equal-Weight on ShockWave Medical, Raises Price Target to $290
Morgan Stanley analyst Cecilia Furlong maintains ShockWave Medical (NASDAQ:SWAV) with a Equal-Weight and raises the price target from $255 to $290.
Shockwave Medical Initiates All-Female Coronary Intravascular Lithotripsy Study To Treat Severely Calcified Cardiovascular Disease
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions
Study Seeks to Confirm Benefits of Shockwave's Coronary IVL in Females Who Historically Have Suffered Less
Expert Ratings for ShockWave Medical
Over the past 3 months, 5 analysts have published their opinion on ShockWave Medical (NASDAQ:SWAV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Ulta Beauty To $511? Here Are 5 Other Price Target Changes For Monday
Barclays boosted the price target on Ulta Beauty, Inc. (NASDAQ: ULTA) from $491 to $511. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Ulta Beauty shares fell 1% to $407.41 in pre-market trading.
10 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.